MY CONTENT

AD is characterized by the accumulation of extracellular amyloid-β in the brain parenchyma and along the walls of cerebral blood vessels, leading to decreased CBF. CBF changes on ASL-MR could reflect clearance of amyloid-β on lecanemab therapy, raising the possibility that ASL-MR could serve as a tool for monitoring the neurovascular treatment response.